Literature DB >> 33516529

Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations.

Chad A Hamilton1, Bhavana Pothuri2, Rebecca C Arend3, Floor J Backes4, Paola A Gehrig5, Pamela T Soliman6, J Spencer Thompson7, Renata R Urban8, William M Burke9.   

Abstract

INTRODUCTION: In 2014, the Society of Gynecologic Oncology's Clinical Practice Committee published a clinical update reviewing the treatment of women with endometrial cancer. At that time, there had been significant advances in the diagnosis, work-up, surgical management, and available treatment options allowing for more optimal care of affected women. Despite these advances, the incidence of endometrial cancer as well as the deaths attributable to the disease have continued to rise; from 1987 to 2014 there has been a 75% increase in cases and almost 300% increase in endometrial cancer deaths. Fortunately, since then, there has been progress in the treatment of patients with endometrial cancer with increased utilization of molecular pathology, greater understanding of genetic predisposition, enhanced methods for lymph node assessment, a broader understanding of the efficacy of radiation and chemotherapy, and a more efficient approach to survivorship and surveillance. The purpose of this document is to present a comprehensive review of this progress. MANUSCRIPT DEVELOPMENT PROCESS: The authors reviewed the available evidence, contributed to the development of this manuscript, provided critical review of the guidelines, and finalized the manuscript recommendations. The review was also presented to and approved by the Society of Gynecologic Oncology (SGO) Clinical Practice Committee, SGO Publications Committee, and the SGO board members prior to submission for publication. The recommendations for this manuscript were developed by a panel of gynecologic oncologists who were members of the SGO Clinical Practice and Education Committees. Panelists reviewed and considered evidence from current uterine cancer literature. The terminology used in these guidelines was adopted from the ASCCP management guidelines [1] using a two-part rating system to grade the strength of recommendation and quality of evidence (Table 1). The rating for each recommendation is given in parentheses.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Endometrial cancer; Fertility preservation; Molecular pathology; Part I; Part II; Recurrence; Risk stratification; Surgery; Surveillance; Survivorship

Mesh:

Year:  2021        PMID: 33516529     DOI: 10.1016/j.ygyno.2020.12.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

Review 1.  Endometrial Cancer: Transitioning from Histology to Genomics.

Authors:  Cristina Mitric; Marcus Q Bernardini
Journal:  Curr Oncol       Date:  2022-01-31       Impact factor: 3.677

2.  Nomograms of Combining Apparent Diffusion Coefficient Value and Radiomics for Preoperative Risk Evaluation in Endometrial Carcinoma.

Authors:  Kaiyue Zhang; Yu Zhang; Xin Fang; Mengshi Fang; Bin Shi; Jiangning Dong; Liting Qian
Journal:  Front Oncol       Date:  2021-07-27       Impact factor: 6.244

3.  Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.

Authors:  Erica Herrera Cappelletti; Jonas Humann; Rafael Torrejón; Pietro Gambadauro
Journal:  Hum Reprod Update       Date:  2022-02-28       Impact factor: 15.610

4.  Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis.

Authors:  Annukka Pasanen; Mikko Loukovaara; Elina Kaikkonen; Alisa Olkinuora; Kirsi Pylvänäinen; Pia Alhopuro; Päivi Peltomäki; Jukka-Pekka Mecklin; Ralf Bützow
Journal:  Cancers (Basel)       Date:  2022-03-06       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.